226 related articles for article (PubMed ID: 23712814)
1. A clinical approach to pharmacogenetics.
de Graaff LC; van Schaik RH; van Gelder T
Neth J Med; 2013 Apr; 71(3):145-52. PubMed ID: 23712814
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Borroni RG
G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests.
Khan DA
J Allergy Clin Immunol; 2016 Oct; 138(4):943-955. PubMed ID: 27720019
[TBL] [Abstract][Full Text] [Related]
4. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
5. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
6. Can pharmacogenetics help rescue drugs withdrawn from the market?
Shah RR
Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacogenetic research in the association between human leukocyte antigen and adverse drug reactions].
Xiong Y; Zhang W; Chen X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):749-57. PubMed ID: 25080918
[TBL] [Abstract][Full Text] [Related]
8. An update on HLA alleles associated with adverse drug reactions.
Fricke-Galindo I; LLerena A; López-López M
Drug Metab Pers Ther; 2017 May; 32(2):73-87. PubMed ID: 28315856
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of mood disorders: what clinicians need to know.
Laje G
CNS Spectr; 2013 Oct; 18(5):272-84. PubMed ID: 24050155
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of adverse reactions to antiepileptic drugs.
Fricke-Galindo I; Jung-Cook H; LLerena A; López-López M
Neurologia (Engl Ed); 2018 Apr; 33(3):165-176. PubMed ID: 25976948
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
Vassy JL; Stone A; Callaghan JT; Mendes M; Meyer LJ; Pratt VM; Przygodzki RM; Scheuner MT; Wang-Rodriguez J; Schichman SA;
Genet Med; 2019 Feb; 21(2):382-390. PubMed ID: 29858578
[TBL] [Abstract][Full Text] [Related]
12. [State of the art of pharmacogenetic diagnostics in drug therapy].
Kirchheiner J; Seeringer A; Brockmöller J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
Shah RR
Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
[TBL] [Abstract][Full Text] [Related]
14. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers.
Tohkin M; Ishiguro A; Kaniwa N; Saito Y; Kurose K; Hasegawa R
Drug Metab Pharmacokinet; 2010; 25(2):122-33. PubMed ID: 20460818
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.
Jaramillo NM; Galindo IF; Vázquez AO; Cook HJ; LLerena A; López ML
Drug Metabol Drug Interact; 2014; 29(2):67-79. PubMed ID: 24406279
[TBL] [Abstract][Full Text] [Related]
16. Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study.
Toh DS; Tan LL; Aw DC; Pang SM; Lim SH; Thirumoorthy T; Lee HY; Tay YK; Tan SK; Vasudevan A; Lateef A; Chong YY; Chan YC; Loke C; Chan CL; Koay ES; Ren EC; Lee EJ; Sung C
Pharmacogenomics J; 2014 Aug; 14(4):316-21. PubMed ID: 24394201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.
Kaniwa N; Saito Y
J Hum Genet; 2013 Jun; 58(6):317-26. PubMed ID: 23635947
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
[TBL] [Abstract][Full Text] [Related]
19. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.
Rufini S; Ciccacci C; Politi C; Giardina E; Novelli G; Borgiani P
Pharmacogenomics; 2015 Nov; 16(17):1989-2002. PubMed ID: 26555663
[TBL] [Abstract][Full Text] [Related]
20. Expectations, validity, and reality in pharmacogenetics.
Limdi NA; Veenstra DL
J Clin Epidemiol; 2010 Sep; 63(9):960-9. PubMed ID: 19995676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
